These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4594 related articles for article (PubMed ID: 20573926)

  • 21. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
    Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
    Watanabe S; Minegishi Y; Yoshizawa H; Maemondo M; Inoue A; Sugawara S; Isobe H; Harada M; Ishii Y; Gemma A; Hagiwara K; Kobayashi K
    J Thorac Oncol; 2014 Feb; 9(2):189-94. PubMed ID: 24419415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
    Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
    Ann Oncol; 2013 Jan; 24(1):54-9. PubMed ID: 22967997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
    Choi YJ; Lee DH; Choi CM; Lee JS; Lee SJ; Ahn JH; Kim SW
    BMC Cancer; 2015 Oct; 15():763. PubMed ID: 26493267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
    Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
    Shi Y; Chen G; Wang X; Liu Y; Wu L; Hao Y; Liu C; Zhu S; Zhang X; Li Y; Liu J; Cao L; Cheng Y; Zhao H; Zhang S; Zang A; Cui J; Feng J; Yang N; Liu F; Jiang Y; Gu C;
    Lancet Respir Med; 2022 Nov; 10(11):1019-1028. PubMed ID: 35662408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
    Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
    Mitsudomi T; Morita S; Yatabe Y; Negoro S; Okamoto I; Tsurutani J; Seto T; Satouchi M; Tada H; Hirashima T; Asami K; Katakami N; Takada M; Yoshioka H; Shibata K; Kudoh S; Shimizu E; Saito H; Toyooka S; Nakagawa K; Fukuoka M;
    Lancet Oncol; 2010 Feb; 11(2):121-8. PubMed ID: 20022809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
    Thongprasert S; Duffield E; Saijo N; Wu YL; Yang JC; Chu DT; Liao M; Chen YM; Kuo HP; Negoro S; Lam KC; Armour A; Magill P; Fukuoka M
    J Thorac Oncol; 2011 Nov; 6(11):1872-80. PubMed ID: 22011650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
    Cappuzzo F; Morabito A; Normanno N; Bidoli P; Del Conte A; Giannetta L; Montanino A; Mazzoni F; Buosi R; Burgio MA; Cerea G; Chiari R; Cortinovis D; Finocchiaro G; Foltran L; Migliorino MR; Tiseo M; Ferrari S; De Marinis F
    Lung Cancer; 2016 Sep; 99():31-7. PubMed ID: 27565910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
    Garcia-Campelo R; Arrieta O; Massuti B; Rodriguez-Abreu D; Granados ALO; Majem M; Vicente D; Lianes P; Bosch-Barrera J; Insa A; Dómine M; Reguart N; Guirado M; Sala MÁ; Vázquez-Estevez S; Caro RB; Drozdowskyj A; Verdú A; Karachaliou N; Molina-Vila MA; Rosell R;
    Lung Cancer; 2020 Dec; 150():62-69. PubMed ID: 33070053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
    Tamiya A; Tamiya M; Shiroyama T; Saijo N; Nakatani T; Minomo S; Tsuji T; Takeuchi N; Omachi N; Kurata K; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
    Med Oncol; 2015 Mar; 32(3):40. PubMed ID: 25616723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
    Watanabe S; Inoue A; Nukiwa T; Kobayashi K
    Anticancer Res; 2015 Dec; 35(12):6957-61. PubMed ID: 26637922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 230.